食道がんの世界市場：競合情勢

2024年、GlobalDataの疫学予測でカバーされている16ヶ国で41万件を超えるECの発症が診断されると予測されます。

化学療法は、進行性または転移性EC患者の治療の基幹を形成します。EC向けに上市した革新的な医薬品は全地域で22種あります。

ECのパイプラインには、あらゆる開発段階にある571の分子があります。登録前段階は2つの分子で構成されているのに対し、フェーズ3パイプラインには22の薬剤が含まれています。

過去10年間に実施された1,753件の臨床試験のうち、8.61％がフェーズIII試験であったのに対し、43.29％がフェーズII試験（フェーズII/III試験を含む）でした。

過去10年間、すべての地域でパートナーシップによる取引が主流であり、北米では47.4％、欧州では44.1％、アジア太平洋では39.8％がパートナーシップによる取引でした。

当レポートでは、世界の食道がん市場について調査分析し、疾患情勢、上市済み薬品とパイプライン薬品の評価、現在と将来の競合情勢などを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 疾患情勢

• 疾患の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬品の評価

• 主な上市済み薬品
• 概要：作用機序別
• 概要：分子タイプ別
• 製品のプロファイルと売上の予測

第5章 価格設定と償還の評価

• 年間治療費
• 価格設定と償還までの時間

第6章 パイプライン薬品の評価

• 中期から後期のパイプライン薬品
• 概要：開発段階別
• 概要：作用機序別
• 概要：分子タイプ別
• 薬品固有のフェーズ移行成功率（PTSR）と承認可能性（LoA）
• 治療領域と適応症固有のPTSRとLoA

第7章 臨床試験の評価

• 過去の概要
• 概要：フェーズ別
• 概要：ステータス別
• 概要：フェーズ別（進行中/計画済みの試験）
• 仮想コンポーネントによる試験
• 試験の概要：地域別
• 単一国/多国間試験：地域別
• スポンサー上位20社と内訳：フェーズ別
• スポンサー上位20社と内訳：ステータス別
• 概要：エンドポイントステータス別
• 概要：人種/民族別
• 登録データ
• 試験施設上位20ヶ国
• 世界の上位20施設
• 実現可能性分析 - 地理的概要
• 実現可能性分析 - ベンチマークモデル

第8章 取引情勢

• 合併、買収、戦略的提携：地域別
• 近年の合併、買収、戦略的提携

第9章 商業的評価

• 主要市場企業

第10章 将来の市場カタリスト

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in Esophageal Cancer therapeutics.

In 2024, more than 410,000 diagnosed incident cases of EC are anticipated in the 16 countries covered in GlobalData's epidemiology forecast.

Chemotherapy forms the backbone of therapy in patients with advanced or metastatic EC. There are 22 innovator drugs marketed for EC across geographies.

The EC pipeline has 571 molecules across all stages of development. The pre-registration phase consists of two molecules, whereas the Phase III pipeline contains 22 drugs.

Of the 1,753 trials conducted in the past 10 years, 8.61% were Phase III trials, whereas 43.29% were Phase II trials (including Phase II/III trials).

Over the past decade, partnerships were the predominant deal type in all regions: for North America, Europe, and Asia-Pacific, partnerships were 47.4%, 44.1%, and 39.8% of deals.

Scope

GlobalData's Esophageal Cancer: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Esophageal Cancer market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Esophageal Cancer market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer